biotech

Agio Pharma Sinks on Midstage Trial

Agio Pharmaceuticals Inc. (NASDAQ: AGIO) saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia ...
Read Full Story »

Cara Therapeutics Wins Big on FDA Breakthrough

Cara Therapeutics Inc. (NASDAQ: CARA) saw its shares make a handy gain on Friday after the company said that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy ...
Read Full Story »

Jefferies Sees 6 Biotechs as Undervalued With Massive Upside

Biotech companies are known for having a high-risk high-reward relationship. The health care sector as a whole has been very positive for investors over the past year, leading some analysts ...
Read Full Story »

Clovis Looks to Cash in on Secondary Offering

Shares of Clovis Oncology Inc. (NASDAQ: CLVS) saw a handy gain in Wednesday’s session after the company priced its secondary offering. This offering comes on the heels of a massive ...
Read Full Story »

Does Eiger BioPharmaceuticals Really Have 400% Upside?

Liana Moussatos of Wedbush Securities assumed coverage of Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) with an Outperform rating. The old price target of $28 was also ratcheted up to $34. What ...
Read Full Story »

Large Insider Buying at Alexion Raises Investors’ Eyebrows

Most of the large biotech outfits in America have gone into a limbo mode. Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) fits that bill despite having a $26.5 billion market cap. Is ...
Read Full Story »

Egalet Stumbles Over FDA Complete Response Letter

Egalet Corp. (NASDAQ: EGLT) saw its shares take a dive early on Tuesday after the company announced that it received a complete response letter (CRL) from the U.S. Food and ...
Read Full Story »

Akcea Therapeutics Announces Potential Pricing for IPO

Akcea Therapeutics has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 9.62 million ...
Read Full Story »

Mersana Therapeutics Closes in on IPO After Announcing Expected Price Range

Mersana Therapeutics has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 5.0 million ...
Read Full Story »

Aldeyra Stumbles Over Mid-Stage Clinical Results

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) saw its shares slide on Wednesday after the company gave an update from its mid-stage trial of topical ocular ADX-102 in patients with allergic conjunctivitis. ...
Read Full Story »

How Omeros Won Big on This FDA Approval

Omeros Corp. (NASDAQ: OMER) saw its shares make a handy gain on Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation ...
Read Full Story »

Why Coherus Biosciences Shares Are Crashing

Coherus Biosciences Inc. (NASDAQ: CHRS) saw its shares crater on Monday after the company announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration ...
Read Full Story »

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

Health care is a sector that has been good to investors so far this year, and some of the top pharmaceutical and biotech companies have posted outstanding results. While there ...
Read Full Story »

Short Interest Surges in Major Biotechs

The short interest data are out for the most recent settlement date, May 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Who Wins From Endo’s Opana Getting Pulled From the Market

In an unprecedented move, the U.S. Food and Drug administration (FDA) requested that Endo International PLC (NASDAQ: ENDP) remove its Opana ER from the market. Ultimately, the agency held concerns ...
Read Full Story »